Remote ischaemic conditioning trial design for patients with acute ischaemic stroke and large-vessel occlusionTrial plans to test arm cuff inflation for stroke recovery

The study is a Phase 3 randomized controlled trial designed to evaluate the efficacy and safety of remote ischaemic conditioning (RIC) in a specific subset of stroke patients. The study is set in a multicentre environment in China. The target population consists of patients diagnosed with acute ischaemic stroke (AIS) caused by large-vessel occlusion in the anterior circulation who are scheduled to undergo mechanical thrombectomy (MT). The planned sample size is between 1526 and 2105 patients.

The intervention involves remote ischaemic conditioning (RIC). This procedure is performed by intermittently inflating cuffs on the upper arm to a pressure of 200 mm Hg. The study is designed to evaluate two different durations for this intervention: a 14-day duration or a 30-day duration. The comparator group will receive standard treatment alone. The primary objective is to determine the proportion of patients achieving functional independence, defined as a modified Rankin Scale (mRS) score of 0-2, at a follow-up period of 90 days.

Secondary outcomes include a shift analysis of mRS scores, early neurological improvement, and infarct volume on imaging. These metrics are intended to provide a more granular understanding of the neurological impact of RIC compared to standard care. However, as this is a rationale and design publication, no primary or secondary outcome results, effect sizes, or p-values are reported. The study is currently ongoing.

Safety and tolerability data are not reported in this publication. The study design aims to monitor for adverse events, serious adverse events, and treatment discontinuations, but these data points remain unavailable at this stage. The protocol is designed to assess whether RIC can be integrated into the standard management of anterior circulation large-vessel occlusion without increasing the risk of complications.

This trial addresses a specific gap in the management of acute ischaemic stroke. While mechanical thrombectomy is a standard of care for large-vessel occlusion, there is ongoing investigation into adjunctive neuroprotective therapies. This study specifically targets the use of RIC as a potentially safe, easy-to-implement, and cost-effective neuroprotective therapy. Unlike some previous studies focusing on different stroke types or populations, this trial focuses specifically on anterior circulation large-vessel occlusion patients undergoing mechanical thrombectomy.

Methodological limitations include the fact that the trial is open-label. Because this is a rationale and design paper, the primary limitation is the complete absence of clinical data. No results are available to inform current practice decisions at this time. The study is designed to provide evidence for a specific intervention, but the lack of reported outcomes means it cannot currently be used to change clinical pathways.

Questions remain regarding the optimal duration of RIC (14 days versus 30 days) and the specific impact on infarct volume. Future results will be necessary to determine if RIC provides a statistically significant improvement in functional independence compared to standard treatment alone. Until the trial is completed and results are published, the clinical utility of RIC remains theoretical based on the proposed study design.